Related Experiment Video
Updated: Jan 6, 2026
09:21
Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
Published on: July 7, 2023
2.0K
Pharmacogenetics in advanced Parkinson's disease.
Jaime Kulisevsky1,2,3,4,5, Pedro García-Ruíz6,7, Tiago Fleming Outeiro8,9
1Medicine Department, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. jkulisevsky@santpau.cat.
Journal of Neural Transmission (Vienna, Austria : 1996)
|November 12, 2025
Summary
Pharmacogenetics and pharmacogenomics can personalize Parkinson's disease (PD) treatment by considering patient genetics. This approach aims to improve medication response predictability, especially in advanced PD cases.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Treatment response to antiparkinsonian medication is unpredictable, particularly in advanced stages.
- Personalized medicine approaches are emerging in other fields like Oncology.
Purpose of the Study:
- To review and comment on updated information regarding pharmacogenetics and pharmacogenomics in PD.
- To explore the potential of genetic information in tailoring PD treatments.
- To highlight the application of personalized pharmacology in managing Parkinson's disease.
Main Methods:
- Literature review and commentary on current research.
- Analysis of pharmacogenetic and pharmacogenomic data relevant to PD.
- Discussion of personalized pharmacology strategies for PD management.
Main Results:
- Pharmacogenetics and pharmacogenomics offer a pathway to personalized PD treatment.
- Genetic background can influence patient response to antiparkinsonian drugs.
- The review synthesizes updated information on this rapidly evolving field.
Conclusions:
- Pharmacogenetic and pharmacogenomic approaches hold promise for optimizing Parkinson's disease therapy.
- Understanding a patient's genetic makeup can lead to more predictable and effective treatment decisions.
- This personalized pharmacology approach could significantly improve outcomes for individuals with PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
201
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
201
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
200
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
200
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234